FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): February 3, 2006

 

ALEXION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   000-27756   13-3648318

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

352 Knotter Drive, Cheshire, Connecticut 06410

(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code: (203) 272-2596

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 7.01 Regulation FD Disclosure.

 

On February 3, 2006, Alexion Pharmaceuticals, Inc. issued a press release with an update on its APEX-AMI pexelizumab trial. A copy of the press release is furnished as Exhibit 99.1 to this form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on February 3, 2006.

 

 

Signature

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

ALEXION PHARMACEUTICALS, INC.

 

Date: February 3, 2006

By:  /s/  Thomas I. H. Dubin                          

        Name: Thomas I. H. Dubin

        Title: Senior Vice President and General Counsel

 

 

Index to Exhibits

 

Exhibit
No.
   

Description

99.1    Press Release issued by Alexion Pharmaceuticals, Inc. on February 3, 2006.